Boehringer and Exelixis to Collaborate in Autoimmune Diseases
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 5 (Table of Contents)
Published: 15 May-2009
DOI: 10.3833/pdr.v2009.i5.1107 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Exelixis and Boehringer Ingelheim have signed an agreement to co-develop drugs that target the sphingosine-1-phosphate type 1 receptor for the treatment of autoimmune diseases in a deal that could be worth a potential US$354 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS